Arvelle Therapeutics International GmbH

Arvelle Therapeutics International GmbH

Arvelle Therapeutics International GmbH

Overview
Date Founded

2019

Headquarters

Zählerweg 6,Zug 6301

Type of Company

Private

Employees (Worldwide)

11 - 50

Industries

Biotechnology
Wholesale: Consumer Non-Durables/Sundries

Company Description

Arvelle Therapeutics GmbH provides treatment for patients suffering form CNS disorders. The company was founded by Ilise Lombrado, Gregory Mark Weinhoff and Mark Altmeyer and is headquartered in Basel, Switzerland.

Executives & Employees

Chief Executive Officer & Founder

Founder & Chief Financial Officer

Founder & Chief Medical Officer

Director

Senior Vice President Commercial

Vice President, Human Resources

Vice President Medical Affairs

Vice President Market Access & Pricing

Vice President, Finance

Vice President Legal Counsel

Board of Directors

Executive Vice President & Chief Operating Officer at Actelion Pharmaceuticals

Founder at LSP Management Group BV

Managing Director, H.I.G. Biohealth Partners at H.I.G. Capital LLC

Partner at F-Prime Capital Partners

Partner at NovaQuest Capital Management LLC

Chief Executive Officer & Founder at Arvelle Therapeutics International GmbH

Paths to Arvelle Therapeutics International GmbH
Potential Connections via
Relationship Science
You
Arvelle Therapeutics International GmbH
Recent Transactions
Details Hidden

Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - SpA, Finaf SpA purchase Arvelle Therapeutics International GmbH from Sio Gene Therapies, Inc., SK Biopharmaceuticals Co., Ltd.

Transaction Advisors
Investment Advisor

Advised onAziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - SpA, Finaf SpA purchase Arvelle Therapeutics International GmbH from Sio Gene Therapies, Inc., SK Biopharmaceuticals Co., Ltd.

Legal Advisor

Advised onAziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - SpA, Finaf SpA purchase Arvelle Therapeutics International GmbH from Sio Gene Therapies, Inc., SK Biopharmaceuticals Co., Ltd.

Legal Advisor

Advised onAziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - SpA, Finaf SpA purchase Arvelle Therapeutics International GmbH from Sio Gene Therapies, Inc., SK Biopharmaceuticals Co., Ltd.

Investors
Details Hidden

Chief Executive Officer & Founder at Arvelle Therapeutics International GmbH

Details Hidden

Founder & Chief Financial Officer at Arvelle Therapeutics International GmbH

Details Hidden

KBIC's investment strategy focuses on firms active in fast-growing sectors such as IT, Internet/software, communication, as well as entertainment businesses. They look for opportunities in Korea and in the global market. Their objective is to increase the value of their investments. They aim to establish a purpose-built fund to respond to each of their areas of investment.They are active, long-term investment partners. KBIC typically works closely with their portfolio firms. They establish a support team for assistance in the finance, legal and marketing.KBIC considers several exit strategies including stock sales and M&As.

Suppliers
SK Biopharmaceuticals Co., Ltd. Pharmaceuticals | Seongnam-si, South Korea

SK Biopharmaceuticals Co., Ltd. engages in the research and development of new drugs and antibiotics. It mainly develops new drugs for central nervous system disorders, and brain tumors. The company was founded in 1993 and is headquartered in Seongnam-si, South Korea.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Arvelle Therapeutics International GmbH. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Arvelle Therapeutics International GmbH's profile does not indicate a business or promotional relationship of any kind between RelSci and Arvelle Therapeutics International GmbH.